New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative ...
-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo --
Source: eagletribune.com
Presented Today News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Presented Today. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Presented Today Today - Breaking & Trending Today
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating ...
Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well
Source: eagletribune.com
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at...
Source: marketscreener.com
Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...
Source: prnewswire.com
EQS-News: Immunic, Inc.: Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
Issuer: Immunic, Inc. / Key word(s): Study/Conference Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action 06.05.2023
Source: finanznachrichten.de